US-based Mylan has launched the authorised generic version of EpiPen (epinephrine injection, USP) auto-injector, after the recent price hike criticism.
The self-injectable device (auto-injector) contains epinephrine, the first-line treatment for life-threatening allergic reactions or anaphylaxis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Expected to reach pharmacies from next week, the authorised generic has the same drug formulation and device functionality as EpiPen auto-injector that is administered in the same way.
Mylan CEO Heather Bresch said: “Americans are rightfully concerned about rising drug prices, and now more than ever patients and families across this country are standing at the pharmacy counter struggling to pay for their medications.
“While it is important to understand the outdated and complex system that determines what someone pays for medicine in the US, hardworking families don’t need an explanation, they need a solution.”
The authorised generic for EpiPen auto-injector is planned to be launched in retail channels soon and is available in strengths of 0.15mg and 0.3mg.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBresch added: “Unfortunately, families will continue to face sticker shock for medications and may be forced to make difficult choices until the pharmaceutical pricing system is reformed to address the increasing shift of costs directly to consumers.
“Pharmaceutical pricing is too far removed from the patient at the pharmacy counter and not designed for today’s increasingly consumerised healthcare system.”
Mylan began in West Virginia more than 55 years ago and its medicines filled one out of 13 of all prescriptions in the US last year, equal to 21 billion doses.
